Minimally INvasive Colon Cancer Surgery Through IMmunomics and Optical Mapping of the Sentinel Lymph Node.

Inclusion Criteria: * Tumor type: proven adenocarcinoma of the colon * Extent of disease (AJCC 7th edition): clinically node negative (stage II) non-metastatic colon cancer * Locally resectable disease * Adequate mental faculty, allowing to understand the proposed treatment protocol and provide informed consent * Laboratory data * Serum creatinine ≤ 1.5 mg/dl or a calculated GFR ≥ 60 mL/min/1.73 m2 * Serum total bilirubin ≤ 1.5 mg/dl, except for known Gilbert's disease * Platelet count \> 100,000/µl * Hemoglobin \> 9g/dl * Neutrophil granulocytes \> 1,500/ml * International Normalized Ratio (INR) ≤ 2 * Absence of alcohol and/or drug abuse * No inclusion in other clinical trials interfering with the study protocol * No concurrent chronic systemic immune therapy, chemotherapy, or hormone therapy * Absence of any severe organ insufficiency * No pregnancy or breast feeding * Adequate contraception in fertile patients * Written informed consent Exclusion Criteria: * Node positive and/or metastatic disease * Locally unresectable disease * Medically unfit patients (Karnofsky index \< 70%) * Allergies to any of the procedural substances (allergy to iodides, hypersensitivity to products containing human albumin)